Literature DB >> 11511958

The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series.

C L Holmes1, K R Walley, D R Chittock, T Lehman, J A Russell.   

Abstract

OBJECTIVE: To review all cases of septic shock treated with vasopressin to determine the effects on hemodynamic and renal function and to document any adverse effects.
SETTING: A 14-bed mixed medical-surgical ICU of St. Paul's Hospital, a 450-bed tertiary referral hospital affiliated with the University of British Columbia. PATIENTS: All ICU patients who received vasopressin for treatment of severe septic shock between August 5, 1997, and March 21, 1999.
RESULTS: We identified 50 patients: age 60 (+/-14); APACHE II score 27 (+/-7). Baseline data (T0) was compared to data at T4, T24 and T48 (4, 24 and 48 h) on infusion. Mean arterial pressure (MAP) increased by 18% from T0 to T4 and remained stable at T24 (p=0.006) and T48 (p=0.008). Systolic pulmonary artery pressure (PAP) was unchanged at 45+/-13 mmHg. Mean cardiac index (CI) decreased by 11% at T4 (p=0.03). Urine output increased 79% at T4 (p=0.005) and further increases were not significant at T24 and T48. Mean pressor dosage decreased by 33% at T4 (p=0.001), by 53% at T24 (p=0.002) and by 48% at T48 (p=0.01). Hospital mortality was 85%. There were six cardiac arrests; all but one occurred at a vasopressin dose of 0.05 U/min or more.
CONCLUSIONS: In this group of patients with severe septic shock, vasopressin infusion increased MAP and urine output and decreased catecholamine requirements. Doses higher than 0.04 U/min were not associated with increased effectiveness and may have been associated with higher adverse effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511958     DOI: 10.1007/s001340101014

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  62 in total

1.  What about vasopressin?

Authors:  D W Ryan; A J Kilner
Journal:  Intensive Care Med       Date:  2002-06       Impact factor: 17.440

2.  Vasopressin for refractory hypotension in extremely low birth weight infants.

Authors:  Margarita Bidegain; Rachel Greenberg; Catherine Simmons; Chi Dang; C Michael Cotten; P Brian Smith
Journal:  J Pediatr       Date:  2010-06-17       Impact factor: 4.406

Review 3.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.

Authors:  Emanuel P Rivers; Lauralyn McIntyre; David C Morro; Kandis K Rivers
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

4.  Arginine-vasopressin in neonates with vasodilatory shock after cardiopulmonary bypass.

Authors:  Evelyn Lechner; Anna Hofer; Rudolf Mair; Werner Moosbauer; Eva Sames-Dolzer; Gerald Tulzer
Journal:  Eur J Pediatr       Date:  2007-01-16       Impact factor: 3.183

Review 5.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

6.  Impact of the Sequence of Norepinephrine and Vasopressin Discontinuation in Patients Recovering From Septic Shock.

Authors:  Benjamin E Bredhold; Shauna D Winters; John C Callison; Robert E Heidel; Lauren M Allen; Leslie A Hamilton
Journal:  Hosp Pharm       Date:  2018-12-05

Review 7.  Clinical sepsis and septic shock--definition, diagnosis and management principles.

Authors:  Jean-Louis Vincent
Journal:  Langenbecks Arch Surg       Date:  2008-06-27       Impact factor: 3.445

Review 8.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series.

Authors:  Stephanie M Boyd; Kristin L Riley; Regan E Giesinger; Patrick J McNamara
Journal:  J Perinatol       Date:  2020-09-19       Impact factor: 2.521

10.  Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report.

Authors:  Lillian Barra; Jeffrey Shum; J Geoffrey Pickering; Raymond Kao
Journal:  J Med Case Rep       Date:  2009-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.